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Abstract
Background: The influence of gender on the expression of COPD has received limited attention.
Quality of Life (QoL) has become an important outcome in COPD patients. The aim of our study
was to explore factors contributing to gender differences in Quality of Life of COPD patients.
Methods: In 146 men and women with COPD from a pulmonary clinic we measured: Saint
George's Respiratory Questionnaire (SGRQ), age, smoking history, PaO2, PaCO2, FEV1, FVC, IC/
TLC, FRC, body mass index (BMI), 6 minute walk distance (6MWD), dyspnea (modified MRC),
degree of comorbidity (Charlson index) and exacerbations in the previous year. We explored
differences between genders using Mann-Whitney U-rank test. To investigate the main
determinants of QoL, a multiple lineal regression analysis was performed using backward Wald's
criteria, with those variables that significantly correlated with SGRQ total scores.
Results: Compared with men, women had worse scores in all domains of the SGRQ (total 38 vs
26, p = 0.01, symptoms 48 vs 39, p = 0.03, activity 53 vs 37, p = 0.02, impact 28 vs 15, p = 0.01).
SGRQ total scores correlated in men with: FEV1% (-0.378, p < 0.001), IC/TLC (-0.368, p = 0.002),
PaO2 (-0.379, p = 0.001), PaCO2 (0.256, p = 0.05), 6MWD (-0.327, p = 0.005), exacerbations (0.366,
p = 0.001), Charlson index (0.380, p = 0.001) and MMRC (0.654, p < 0.001). In women, the scores
correlated only with FEV1% (-0.293, p = 0.013) PaO2 (-0.315, p = 0.007), exacerbations (0.290, p =
0.013) and MMRC (0.628, p < 0.001). Regression analysis (B, 95% CI) showed that exercise capacity
(0.05, 0.02 to 0.09), dyspnea (17.6, 13.4 to 21.8), IC/TLC (-51.1, -98.9 to -3.2) and comorbidity (1.7,
0.84 to 2.53) for men and dyspnea (9.7, 7.3 to 12.4) and oxygenation (-0.3, -0.6 to -0.01) for women
manifested the highest independent associations with SGRQ scores.
Conclusion: In moderate to severe COPD patients attending a pulmonary clinic, there are gender
differences in health status scores. In turn, the clinical and physiological variables independently
associated with those scores differed in men and women. Attention should be paid to the
determinants of QoL scores in women with COPD.
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Chronic Obstructive Pulmonary Disease (COPD) prima-
rily affects the airway and lung parenchyma while it also
induces clinically important systemic consequences. For
an appropriate diagnosis and follow up a multidimen-
sional evaluation of the disease is required including:
degree of airway obstruction, lung hyperinflation, dysp-
nea, exercise capacity, quality of life and nutritional status.
The influence of gender on the clinical expression of
COPD has received limited attention. The lack of informa-
tion regarding gender and COPD is surprising, because
according to the recent COPD disease surveillance in the
United States [1], for the first time in 2002, the number of
women dying from this disease surpassed that of men.
Quality of Life has become an important measurable out-
come in patients with Chronic Obstructive Pulmonary
Disease (COPD). It is known to predict mortality [2], hos-
pitalization [3], health care resource utilization [3] and
response to different treatment options [4]. The Saint
George's Respiratory Questionnaire (SGRQ) has become
one of the most widely used health-related specific ques-
tionnaires for assessing QoL in respiratory patients [5].
In the literature there are few reports suggesting a greater
impairment in health related quality of life in female
patients with COPD [6-10]. Several studies completed
mainly in men with COPD, have explored the physiolog-
ical and psychological factors associated with QoL impair-
ment [11-14]. They have shown that dyspnea, six minute
walk distance (6MWD), PaO2, FEV1, anxiety and depres-
sion are associated with the QoL scores in these patients.
In a previous study [15], we found that in a FEV1%
matched population of COPD patients, women had
worse SGRQ scores than men at younger age and earlier
stage of the disease. We planned the present study in a
larger sample, to explore possible gender differences in
the factors associated and predictive of SGRQ scores in
both genders.
Methods
This FEV1 matched case series study, recruited COPD
patients attending the pulmonary clinic at Hospital Uni-
versitario Ntra Sra de Candelaria, a tertiary public univer-
sity hospital in Spain from January 2000 to December
2005. We recruited 73 consecutive women attending the
clinic and then matched 73 patients with similar degree of
airflow obstruction randomly selected from our much
larger population of men with COPD. Patients with all
degree of airflow severity were included if they had
smoked ≥ 20 pack years and had a post-bronchodilator
FEV1/FVC of <0.7 after 400 micrograms of inhaled
albuterol. Patients were excluded if they had a history of
asthma, has a history of bronchiectasis, tuberculosis or
other confounding diseases. The patients were clinically
stable (no exacerbation for at least 2 months) at the time
of the evaluation and were part of the population studied
for the BODE international multicenter study [16]. The
Ethical Committee of the Hospital approved the study
and all patients signed the informed consent.
We evaluated the QoL of the study sample by the SGRQ.
We also measured proven prognostic parameters for
COPD patients: age, degree of airflow obstruction by
FEV1, dyspnea by the Modified Medical Research Council
scale (MMRC), exercise capacity by the Six Minute Walk
Distance (6MWD) and the presence of comorbidities by
the combined Charlson index [17] where the higher the
score, the more co-morbidities are present, and the exac-
erbations in the previous year of the study date.
Postbronchodilator FEV1, FVC, FEV1/FVC and IC/TLC
were determined taking the European Community for
Steel and Coal for Spain reference [16] using a Jaegger 920
MasterLab® Body Box. BMI was calculated as the weight in
kilograms divided by height in meters2. Arterial blood
gases were measured at rest.
Exacerbations were defined as episodes of increased dys-
nea, production of phlegm and cough that required med-
ical attention, differentiating those that required
admission and those that did not for one full year.
The 6MWD was performed following the ATS guidelines
[19] using as reference values those of Troosters et al [18].
Functional dyspnea was measured using the ATS modified
MMRC [21]. Health status was determined using the lan-
guage-specific validated SGRQ questionnaire that pro-
vides three individual domain scores: symptoms, activity,
impact (psychosocial dysfunction). A total score is calcu-
lated, with zero indicating no impairment and 100 repre-
senting maximum impairment [5].
We used the following gender matching method: from an
initial sample of 110 males and 73 females with COPD;
we were able to match every female patient with a male
with FEV1% of predicted ± 2%; when more than one male
matched, we chose the male patient to be included in the
final sample by random drawing from a list while being
blinded to the rest of the parameters included in this
study. The matching process was done prospectively and
at the time of diagnosis. A sample of 73 patients in each
group allowed us to detect a relevant difference as small as
10 points for SGRQ scores, in a two-tailed test at 5% sig-
nificant level with a power of 85%, considering a median
SGRQ value of 30 points for men and 40 for women.Page 2 of 7
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(25th percentile-75th percentile) depending on their distri-
bution. We explored for differences between genders in
each parameter using Student t-test for variables with
approximately normal distribution, Mann-Whitney U-
rank test for variables without normal distribution. We
then correlate SGRQ Total scores with the different stud-
ied variables. A multiple linear regression analysis was
performed using backward Wald's criteria, with those var-
iables that significantly correlated with SGRQ Total
scores. A p value ≤ 0.05 was considered statistically signif-
icant.
Results
The patients were white Caucasian and when enrolled,
25% of the men and 23% of the women were still smok-
ing. None of the patients had a history of exposure to bio-
mass fuel. Using the GOLD staging system [22] we have
equal number of men and women in each GOLD Stage (I
13%, II 43%, III 36%, IV 5%).
The clinical and physiological characteristics of the
patients participating in the study are described in Table 1.
Women were younger and smoked less than men. There
were no differences in current smoking status. Women
had lower BMI and a higher percentage of them had a BMI
≤ 21. Women had less co-morbidities and more exacerba-
tions in the previous year than men. No differences were
found in FRC% predicted. Women had a higher PaO2 and
lower PaCO2 than men. Even though they had the same
predicted FEV1 and better mean PaO2, women had a lower
6MWD in % of predicted values and reported more func-
tional dyspnea. They also scored worse in all domains of
the SGRQ.
When we compared SGRQ scores for the population
divided by FEV1% in greater and lower than 50%, there
were gender differences only for the group with FEV1
>50% group [n = 43 for each gender, p < 0.05 in all com-
parisons, men and women respectively: total 17(6–30) vs
32 (25–42), symptoms 31(11–44) vs 42(28–56), activity
23 (8–40) vs 53 (43–56) and impact 8 (5–26) vs 20 (13–
35)]. We did not find differences for the more severe
group of patients (FEV1% <50%, GOLD stages III and IV).
Those parameters that significantly correlated with SGRQ
total scores are shown in Table 2 for the entire population
and divided by gender. There were gender differences in
the parameters that correlated with SGRQ.
Table 3 shows multiple linear regressions of those factors
that significantly correlated with SGRQ Total scores
divided by gender. Once again, the factors that predict
SGRQ total scores differed by gender. Figure 1 shows the
relative weight of the studied factors retained in the mul-
tiple linear logistic regression analysis as predictors of the
Table 1: Comparisons of clinical and physiological characteristics between women and men matched by their predicted FEV1
Clinical & Physiological Characteristics Men (n = 73) Women (n = 73) p Value
Age (years old) 63 ± 8* 56 ± 11* <0.001
Age range 47–77 37–79
Pack-years history 69 ± 26* 47 ± 22* <0.001
BMI (kg/m2) 27 ± 4* 25 ± 7* 0.04
BMI ≤ 21(%) 6 32 0.007
Charlson Index (points) 3 (1–6) + 1 (1–3) + <0.001
MMRC (points)
0–2 (%) 93 71 <0.001
3–4 (%) 7 29
Exacerbations in the last year
Without admission 0 (0–1) + 1 (0–2) + 0.013
With admission 0 (0-0) + 0 (0–1) + 0.116
FRC % of predicted 142 ± 31* 134 ± 32* 0.470
IC/TLC ≤ 0.25 (%) 8 (11) 7 (10) 0.627
PaO2 (mmHg) 70 ± 11* 76 ± 11* 0.004
PaCO2 (mmHg) 45 ± 6* 40 ± 5* <0.001
6MWD (mts) 529 ± 93* 459 ± 79* <0.001
6MWD % of Predictive 107 ± 21* 85 ± 17* <0.05
SGRQ
Total 26 (15–52) + 38 (30–47) + 0.011
Symptoms 39 (12–53) + 48 (32–58) + 0.028
Activity 37 (14–62) + 53 (40–62) + 0.020
Impact 15 (6–45) + 28 (13–40) + 0.013
*represents mean ± SD; + represents median and 25th-75th percentilesPage 3 of 7
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We used the β coefficients of the parameters retained in
the regression model to calculate de proportional weight
that each has to predict the variance of the SGRQ total
score.
Discussion
The most important finding of this study is that in moder-
ate to severe COPD patients attending a pulmonary clinic
the factors associated with SGRQ total score are different
in men and women. Whereas dyspnea, exercise capacity,
degree of hyperinflation and comorbidity show an inde-
pendent association with the scores in men, only dyspnea
and level of arterial oxygenation contributed to the score
in women.
The information about gender differences in QoL of
patients with COPD is scarce [6-10]. Osman et al included
266 severe COPD (123 men, 115 women) to investigate if
QoL (measured by the SGRQ) could predict hospital
readmission. Even though this was not an FEV1 matched
population and comparison of gender differences was not
the main goal of the study, they noted worse scores in
women than in men. Leidy et al compared the functional
performance of 45 women and 44 men with COPD using
the Sickness Impact Profile. They reported no significant
differences in all categories but indicated gender differ-
ences in models of functional performance. Larson and
co-workers also reported worse QoL scores in women.
Rodrigue et al [9] showed that in a population of COPD
who underwent lung transplantation, women reported
worse scores and less improvement in QoL after surgery
although they had a greater improvement in their spiro-
metric values. Recently Di Marco et al [10] reported in a
population of 202 COPD patients, worse symptom-
related QoL, and more anxiety and depressive symptoms
in female patients compared with men. However, all of
these authors did not match for degree of airflow limita-
tion and they did not explore differences in the factors
that could help explain the worse scores in women.
As an extension to our previous published study [15], we
planned this study to investigate the possible factors asso-
ciated to this gender differences. We observed that SGRQ
scores in all domains were higher in female patients than
men. The gender differences were all higher than the 4
points considered clinically significant for SGRQ [23].
Surprisingly, when we classified the patients by severity of
obstruction into FEV1% greater and lower than 50%, only
women with mild to moderate disease (GOLD stages II
and II) had higher (worse) scores in all domains of the
SGRQ, than the men. There were no differences in any
domain for Stage III and IV patients.
This is an interesting finding considering that female with
FEV1% <50% were younger than males (53 ± 9 vs. 66 ± 8,
Table 3: Multiple lineal regressions with parameters that significantly correlated with SGRQ total
Quality of Life Group Parameter B (95%CI) p value
SGRQ total Entire population r2 = 0.52 Charlson 1.63 (0.89–2.37) <0.001
MMRC 14.6 (11.7, 17.4) <0.001
Males r2 = 0.87 Charlson 1.68 (0.84, 2.53) <0.001
IC/TLC -51.1 (-98.9, -3.2) 0.037
MMRC 17.6 (13.4–21.8) <0.001
6MWD 0.05 (0.02–0.09) 0.002
Females r2 = 0.48 MMRC 9.7 (7.3–12.4) <0.001
PaO2 -0.3 (-0.6, -0.01) 0.042
Table 2: Studied parameters that significantly correlated with SGRQ total scores.
Studied parameters Entire population Male Females
FEV1% of predictive -0.378 (p < 0.001) -0.479 (p < 0.001) -0.293 (p = 0.013)
IC/TLC -0.306 (p = 0.001) -0.368 (p = 0.002) NS
PaO2 (mmHg) -0.269 (p = 0.001) -0.379 (p = 0.001) -0.315 (p = 0.007)
PaCO2 (mmHg) NS 0.256 (p = 0.057) NS
6MWD (mts) 0.267 (0.002) -0.327 (p = 0.005) NS
Exacerbations 0.343 (p < 0.001) 0.366 (p = 0.001) 0.290 (p = 0.013)
Charlson Index 0.210 (p = 0.012) 0.380 (p = 0.001) NS
MMRC (points) 0.659 (p < 0.001) 0.654 (p < 0.001) 0.628 (p < 0.001)
We show correlation coefficients and p values for those that showed statistical significant correlation
Spearman's coefficients for all correlationsPage 4 of 7
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that women with COPD develop symptoms influencing
the SGRQ questionnaire at a younger age and with less
degree of obstruction than men. Classically, we know that
QoL impairment starts to be noticed when FEV1% falls
below 50% [24]. Our findings imply that females with
COPD differ from males in having an earlier repercussion
of the disease (even at predicted FEV1 values between 65–
80%). This suggests that we should pay more attention to
the early detection of the disease in women. Indeed, the
early age of onset of impairment in QoL in women should
raise alarm considering that most of the primary care phy-
sicians do not think in COPD when they see females with
typical symptoms of cough, phlegm or dyspnea [25]. It is
also important since the impairment of QoL in female
could run for longer time and the response to different
treatment options aimed at improving QoL, like pulmo-
nary rehabilitation, are not the same in females and males
with COPD [26].
In this study we also show that the variables that corre-
lated with SGRQ scores differed by gender (Table 2). If we
only consider the SGRQ total score as a summary of the
QoL expression, the parameters that correlated in men
(FEV1, IC/TLC, PaO2, PaCO2, exacerbations, Charlson,
6MWD and MMRC) were different from those in women
The diagrams shows the relative weight of the factors retained in the logistic regression analysis as predictors of the SGRQ total sco es for male and femal COPD pa ientsFigure 1
The diagrams shows the relative weight of the factors retained in the logistic regression analysis as predictors of the SGRQ 
total scores for male and female COPD patients. SGRQ total = Saint George's Respiratory Questionaire total score. MMRC = 
Modified Medical Research Council scale. 6MWD = Six minute walking distance test. Charlson = Charlson index. IC/TLC = 
Inspiratory Capacity/Total Lung Capacity ratio. PaO2 = Arterial oxygen pressure.Page 5 of 7
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in-line with those reported by Tsukino et al [9] in a pre-
dominatly male COPD cohort, which provides external
validity to our findings. We then can speculate that the
factors affecting QoL differ by gender at least in the early
stages of the disease and that the perceived expression of
the disease is different between genders.
Table 3 summarizes the associated predictors of SGRQ
total scores for males and females with COPD with the
same degree of airway obstruction. The difference
between genders constitutes the most important finding
of our work. While factors like dyspnea, exercise capacity,
degree of hiperinflation and comorbidities explain almost
90% of the variation of the SGRQ total score in our male
patients, dyspnea and level of arterial oxygenation only
explained 50% of the variation of it in the female popula-
tion. It suggests that the female COPD population is
entirely different and that we should look for possible fac-
tors to be included in their regular evaluation to try to
explain the greater and earlier impairment of their QoL.
Dyspnea continues to be the most important driving force
of the QoL impairment in patients with COPD and thera-
pies aiming at relieving this cardinal symptom are impor-
tant in COPD women as well as the close follow up of
their degree of arterial oxygenation. We know that psycho-
logical factors have an important impact in QoL of COPD
patients [13], with a higher prevalence of depression and
anxiety in female COPD patients [10]. We also know from
previous works that female coping mechanisms with
COPD are different that those from males [7]. We then
especulate, as also recently suggested by Di Marco et al
[10] that the evaluation of factors like the psychological or
socio-cultural ones are possible venues that should be
investigated in the female COPD population in order to
explain their impaired QoL.
We believe our study has several limitations. First, our
patients were recruited from those attending a pulmonary
clinic and therefore may not represent the COPD popula-
tion at large. Second, our findings in women may only be
applicable to patients with cigarette related COPD and
not to patients with COPD due to biomass fuel [27].
Third, we did not include depression and anxiety evalua-
tions in the parameters considered, because the study was
designed to explored physiologic factors previously asso-
ciated with health-related quality of life in patients with
COPD. Also, we also did not include generic question-
naires like the SF-36, in the evaluation of the QoL of these
patients, as some investigators believe are complementary
of the specific ones. Considering the scarce information in
the area of QoL in women with COPD, it would have
been important to include them to better reflect all aspects
of the QoL impairment. Lastly, our population study
mainly represents GOLD stages II and III and conclusions
can only be referred to this degree of obstruction. Never-
theless, the main differences found in SGRQ scores are in
the early stages of the disease, and we believe the conclu-
sions here found represent an important message because
most of the patients seen at pulmonary clinics have simi-
lar characteristics as ours.
Conclusion
In summary, our study shows that factors associated with
QoL of moderate to severe COPD patients differ by gen-
der. The main predictors of SGRQ total score in men are
dyspnea, exercise capacity, degree of hyperinflation and
comorbidity, whereas for women, the main predictors are
dyspnea and level of arterial oxygenation. Most impor-
tantly, our data suggests that to appropiately evaluate QoL
in women with COPD, prognostic factors other than the
traditional ones should be included because these do not
fully predict the health related quality of life scores.
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